Biomarker study for people who can't take cisplatin chemo
Part of Cancer clinical trials.
This study looks at immune system markers in patients with head and neck cancer who cannot receive the standard chemotherapy drug cisplatin. The goal is to understand how well a different chemotherapy drug (docetaxel) combined with radiation works in these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer called squamous cell carcinoma of the oropharynx, larynx, or oral cavity.
- You are scheduled to receive chemotherapy plus radiation as your primary or post-surgery treatment.
- You cannot take cisplatin due to reasons like poor kidney function, hearing loss, nerve problems, or other health issues.
- You are willing to provide blood, saliva, and stool samples for research.
- You are 18 years or older and able to understand and agree to the study.
- You do not have cancer that has spread to distant parts of the body or another active cancer (except certain skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a remote hearing test to monitor hearing changes in patients with head and neck cancer getting cisplatin chemotherapy and/or radiation. The goal is to catch hearing loss early so treatment can be adjusted.
This study looks at “immune signals” in blood, saliva, and stool to learn more about head and neck cancers (especially squamous cell carcinoma). It may help researchers find patterns that improve understanding of disease or how treatment should be guided.
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
This trial studies whether adding cisplatin (a chemotherapy medicine) to radiation therapy helps people with stage III–IVA squamous cell cancer of the head and neck after they’ve had surgery. It’s meant to lower the risk of the cancer coming back.
This study collects blood and tumor tissue samples to analyze biological markers in patients with advanced head and neck squamous cell carcinoma before starting immunotherapy. The goal is to better understand how these markers relate to treatment response.
This study looks at how well people swallow and how their quality of life changes during standard chemo-radiation for newly diagnosed throat (oropharyngeal) cancer. The goal is to better understand swallowing side effects so care can improve.
Hear when a new Squamous Cell Carcinoma of the Hypopharynx trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.